AU2021230529B2 - Use of compounds in the treatment of fungal infections - Google Patents

Use of compounds in the treatment of fungal infections Download PDF

Info

Publication number
AU2021230529B2
AU2021230529B2 AU2021230529A AU2021230529A AU2021230529B2 AU 2021230529 B2 AU2021230529 B2 AU 2021230529B2 AU 2021230529 A AU2021230529 A AU 2021230529A AU 2021230529 A AU2021230529 A AU 2021230529A AU 2021230529 B2 AU2021230529 B2 AU 2021230529B2
Authority
AU
Australia
Prior art keywords
spp
compound
solvate
pharmaceutically acceptable
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021230529A
Other languages
English (en)
Other versions
AU2021230529A1 (en
Inventor
Michael Hodges
Karen Joy Shaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Basilea Pharmaceutica International AG
Original Assignee
Basilea Pharmaceutica International AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica International AG filed Critical Basilea Pharmaceutica International AG
Publication of AU2021230529A1 publication Critical patent/AU2021230529A1/en
Assigned to BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL reassignment BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL Request for Assignment Assignors: AMPLYX PHARMACEUTICALS, INC.
Application granted granted Critical
Publication of AU2021230529B2 publication Critical patent/AU2021230529B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021230529A 2020-03-04 2021-03-02 Use of compounds in the treatment of fungal infections Active AU2021230529B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062985274P 2020-03-04 2020-03-04
US62/985,274 2020-03-04
PCT/US2021/020471 WO2021178406A1 (en) 2020-03-04 2021-03-02 Use of compounds in the treatment of fungal infections

Publications (2)

Publication Number Publication Date
AU2021230529A1 AU2021230529A1 (en) 2022-09-29
AU2021230529B2 true AU2021230529B2 (en) 2024-09-05

Family

ID=77612811

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021230529A Active AU2021230529B2 (en) 2020-03-04 2021-03-02 Use of compounds in the treatment of fungal infections

Country Status (11)

Country Link
US (2) US12521406B2 (https=)
EP (1) EP4114405A4 (https=)
JP (1) JP2023516648A (https=)
KR (1) KR20220148881A (https=)
CN (1) CN115515599A (https=)
AU (1) AU2021230529B2 (https=)
BR (1) BR112022017653A2 (https=)
CA (1) CA3174065A1 (https=)
IL (1) IL296093A (https=)
MX (1) MX2022010804A (https=)
WO (1) WO2021178406A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3187268A1 (en) * 2020-06-17 2021-12-23 Amplyx Pharmaceuticals, Inc. Compounds and methods for treating fungal infections
CN116687929B (zh) * 2023-06-16 2026-04-28 山东省妇幼保健院 血根碱在制备防治临床罕见真菌相关感染性疾病药物中的应用
WO2026020112A1 (en) * 2024-07-19 2026-01-22 Sun Pharmaceutical Industries, Inc. Oral formulations of deuruxolitinib
CN119915948B (zh) * 2025-04-02 2025-07-08 天津辰欣药物研究有限公司 一种小分子真菌肌醇酰基转移酶1抑制剂原料药中致突变杂质的分析方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020047510A1 (en) * 2018-08-31 2020-03-05 Amplyx Pharmaceuticals, Inc. Compounds and methods for treating fungal infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
EP2345641A1 (en) 2009-12-29 2011-07-20 Polichem S.A. New secondary 8-hydroxyquinoline-7-carboxamide derivatives
EP2636409A1 (en) * 2010-11-05 2013-09-11 Eisai R&D Management Co., Ltd. Combined pharmaceutical composition as antifungal agent
IL275121B2 (en) * 2017-12-07 2025-11-01 Amplyx Pharmaceuticals Inc Heterocycle substituted pyridine derivative antifungal agents
CA3187268A1 (en) 2020-06-17 2021-12-23 Amplyx Pharmaceuticals, Inc. Compounds and methods for treating fungal infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020047510A1 (en) * 2018-08-31 2020-03-05 Amplyx Pharmaceuticals, Inc. Compounds and methods for treating fungal infections

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Alkhazraji, S., et al., ‘Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis’, Antimicrobial Agents and Chemotherapy 2020. *
Covel, J., et al., ‘The discovery of manogepix/fosmanogepix and other gwt1 inhibitors for the treatment of invasive fungal infections’ Medicinal Chemistry Reviews (2019), 54, 221-237 *
Gebremariam, T., et al., ‘726. APX001 (Fosmanogepix) Is Effective in an Immunosuppressed Mouse Model of Rhizopus oryzae Infection’, Open Forum Infectious Diseases, Volume 6, Issue Supplement_2, October 2019, Pages S325–S326 *
Gintjee, T.J., et al., ‘Aspiring Antifungals: Review of Current Antifungal Pipeline Developments’, Journal of Fungi (2020), 6(1), 28 *
Hodges M.R. et al., ‘First-in-human study to assess safety, tolerability and pharmacokinetics of APX001 administered by intravenous infusion to healthy subjects’, Open Forum Infectious Diseases, 2017 Vol. 4, Supp. Supplement 1, pp S526. *
Hodges M.R., et al., ‘Phase 1 study to assess safety, tolerability and pharmacokinetics of single and multiple oral doses of APX001... ’, Open Forum Infectious Diseases, 2017 Vol. 4, Supp. Supplement 1, pp. S534 *
Lima, S.L., et al., ‘Fungal Cell Wall: Emerging Antifungals and Drug Resistance’, Front. Microbiol. 10:2573 *
Pfaller M.A., et al., ‘In Vitro Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017’, Antimicrobial Agents and Chemotherapy 2019. *
Rivero-Menendez, O., et al., ‘In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies’, Journal of Antimicrobial Chemotherapy (2019), 74(5), 1295-1299 *

Also Published As

Publication number Publication date
US20260102419A1 (en) 2026-04-16
CA3174065A1 (en) 2021-09-10
AU2021230529A1 (en) 2022-09-29
NZ792042A (en) 2025-09-26
JP2023516648A (ja) 2023-04-20
EP4114405A4 (en) 2024-03-13
WO2021178406A1 (en) 2021-09-10
KR20220148881A (ko) 2022-11-07
US12521406B2 (en) 2026-01-13
EP4114405A1 (en) 2023-01-11
US20230102036A1 (en) 2023-03-30
CN115515599A (zh) 2022-12-23
BR112022017653A2 (pt) 2022-10-18
MX2022010804A (es) 2023-01-16
IL296093A (en) 2022-11-01

Similar Documents

Publication Publication Date Title
AU2021230529B2 (en) Use of compounds in the treatment of fungal infections
TWI322689B (en) Method for treating severe heart failure and medicament therefor
JP7793681B2 (ja) 真菌感染症を処置するための化合物および方法
WO2016131100A1 (en) Methods of treating infectious diseases
CN110494140A (zh) 用于自闭症谱系障碍药物治疗的方法
US20230233576A1 (en) Eclitasertib for use in treating conditions involving systemic hyperinflammatory response
TW202333731A (zh) 用於治療癌症之VCP/p97抑制劑
AU2021293911B2 (en) Compounds and methods for treating fungal infections
JP3455633B2 (ja) 潰瘍性大腸炎の予防又は治療剤
RU2805930C1 (ru) Использование соединений при лечении грибковых инфекций
JP7454905B2 (ja) 有効成分であるイサブコナゾール又はそのプロドラッグを含有する真菌症治療及び／又は予防剤
US20240245666A1 (en) Dosing regimens
HK40086224A (zh) 化合物在真菌感染的治疗中的用途
RU2824066C1 (ru) Соединения и способы для лечения грибковых инфекций
HK40085944A (en) Compounds and methods for treating fungal infections
TWI920017B (zh) 用於治療真菌感染之化合物及方法
CN119522109A (zh) 用于钙调磷酸酶抑制剂的间歇性给药的组合物
CN1284873A (zh) 水性液体制剂
CN118632692A (zh) 用于治疗肌萎缩侧索硬化症或抑制肌萎缩侧索硬化症进展的药剂
ULC et al. Pr Caspofungin Acetate for Injection
Orosz Aspergillosis, why?

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL

Free format text: FORMER APPLICANT(S): AMPLYX PHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)